Antares Pharma, Inc. (NASDAQ:ATRS) Short Interest Down 34.3% in May

Antares Pharma, Inc. (NASDAQ:ATRSGet Rating) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 4,780,000 shares, a decrease of 34.3% from the April 30th total of 7,280,000 shares. Based on an average trading volume of 4,620,000 shares, the short-interest ratio is currently 1.0 days. Approximately 2.9% of the shares of the stock are sold short.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC acquired a new position in shares of Antares Pharma in the 1st quarter valued at about $336,000. Rice Hall James & Associates LLC lifted its stake in shares of Antares Pharma by 0.6% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,218,851 shares of the specialty pharmaceutical company’s stock valued at $4,997,000 after purchasing an additional 7,500 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Antares Pharma by 10.8% in the 1st quarter. Jane Street Group LLC now owns 36,284 shares of the specialty pharmaceutical company’s stock valued at $149,000 after purchasing an additional 3,535 shares in the last quarter. Douglass Winthrop Advisors LLC acquired a new position in shares of Antares Pharma in the 1st quarter valued at about $41,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Antares Pharma by 4.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,191,359 shares of the specialty pharmaceutical company’s stock valued at $4,885,000 after purchasing an additional 51,656 shares in the last quarter. Hedge funds and other institutional investors own 50.41% of the company’s stock.

NASDAQ ATRS opened at $5.59 on Friday. The business’s 50-day moving average price is $5.03 and its 200 day moving average price is $4.04. Antares Pharma has a twelve month low of $3.11 and a twelve month high of $5.60. The company has a market capitalization of $955.06 million, a PE ratio of 23.29 and a beta of 1.15. The company has a current ratio of 3.08, a quick ratio of 2.87 and a debt-to-equity ratio of 0.10.

Antares Pharma (NASDAQ:ATRSGet Rating) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter. Antares Pharma had a return on equity of 7.43% and a net margin of 21.90%. The business had revenue of $41.56 million for the quarter, compared to analysts’ expectations of $44.01 million. Equities analysts predict that Antares Pharma will post 0.08 EPS for the current year.

A number of research analysts recently weighed in on the company. LADENBURG THALM/SH SH lowered Antares Pharma from a “buy” rating to a “neutral” rating in a report on Thursday, April 14th. Raymond James lowered Antares Pharma from a “strong-buy” rating to a “market perform” rating in a report on Thursday, April 14th. StockNews.com lowered Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, May 16th. Zacks Investment Research lowered Antares Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Finally, Piper Sandler lowered Antares Pharma from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $6.00 to $5.60 in a report on Thursday, April 14th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat, Antares Pharma currently has a consensus rating of “Hold” and a consensus price target of $5.76.

About Antares Pharma (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Read More

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.